Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia

Summary

The β-blocker propranolol, originally designed for cardiological indications (angina, cardiac arrhythmias and high blood pressure), is nowadays, considered the most efficient drug for the treatment in infantile haemangiomas (IH), a vascular tumour that affects 5–10% of all infants. However, its potential therapeutic benefits in other vascular anomalies remain to be explored. In the present work we have assessed the impact of propranolol in endothelial cell cultures to test if this drug could be used in the vascular disease hereditary haemorrhagic telangiectasia (HHT). This rare disease is the result of abnormal angiogenesis with epistaxis, mucocutaneous and gastrointestinal telangiectases, as well as arteriovenous malformations in several organs, as clinical manifestations. Mutations in Endoglin (ENG) and ACVLR1 (ALK1) genes, lead to HHT1 and HHT2, respectively. Endoglin and ALK1 are involved in the TGF-β1 signalling pathway and play a critical role for the proper development of the blood vessels. As HHT is due to a deregulation of key angiogenic factors, inhibitors of angiogenesis have been used to normalise the nasal vasculature eliminating epistaxis derived from telangiectases. Thus, the antiangiogenic properties of propranolol were tested in endothelial cells. The drug was able to decrease cellular migration and tube formation, concomitantly with reduced RNA and protein levels of ENG and ALK1. Moreover, the drug showed apoptotic effects which could explain cell death in IH. Interestingly, propranolol showed some profibrinolytic activity, decreasing PAI-1 levels. These results suggest that local administration of propranolol in the nose mucosa to control epistaxis might be a potential therapeutic approach in HHT.

Keywords

Propranolol - HHT - endoglin - ALK1 - epistaxis

• References

• 1 Black JW, Duncan WA, Shanks RG. Comparison of some properties of pronethalol and Propranolol. Br J Pharmacol Chemother 1965; 25: 577-591.
• 2 Zimmermann AP, Wiegand S, Werner JA. et al. Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolaryngol 2010; 74: 338-342.
• 3 Sanchez-Perez RS, Mora PC, Rodriguez JD. et al. Treatment of infantile hemangioma with Propranolol. An Pediatr (Barc) 2009; 72: 152-154.
• 4 Sanchez-Carpintero I, Ruiz-Rodriguez R, Lopez-Gutierrez JC. Propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations. Actas dermosifiliogr 2011; 102: 766-779.
• 5 Leaute-Labreze C, Dumas de la, Roque E, Hubiche T. et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651.
• 6 Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010; 163: 269-274.
• 7 Lamy S, Lachambre MP, Lord-Dufour S. et al. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 2010; 53: 200-208.
• 8 Annabi B, Lachambre MP, Plouffe K. et al. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 2009; 60: 438-445.
• 9 Sommers-Smith Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 2002; 38: 298-304.
• 10 Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54: 714-729.
• 11 Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009; 17: 860-871.
• 12 Johnson DW, Berg JN, Baldwin MA. et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13: 189-195.
• 13 McAllister KA, Grogg KM, Johnson DW. et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 08: 345-351.
• 14 Gallione CJ, Repetto GM, Legius E. et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004; 363: 852-859.
• 15 Gallione CJ, Richards JA, Letteboer TG. et al. SMAD4 mutations found in uns-elected HHT patients. J Med Genet 2006; 43: 793-797.
• 16 Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24: 203-219.
• 17 Morales-Angulo C, del Valle-Zapico A. Hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1998; 119: 293.
• 18 Plauchu H, de Chadarevian JP, Bideau A. et al. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32: 291-297.
• 19 Zarrabeitia R, Albiñana V, Salcedo M. et al. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT). Curr Vasc Pharmacol 2010; 08: 473-481.
• 20 Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F. et al. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb Haemost 2007; 97: 254-262.
• 21 Morales-Angulo C, Perez del Molino A, Zarrabeitia R. et al. Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid. Acta Otorrinolaringol Esp 2007; 58: 129-132.
• 22 de Gussem EM, Snijder RJ, Disch FJ. et al. The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. Rhinology 2009; 47: 85-88.
• 23 Albiñana V, Bernabeu-Herrero ME, Zarrabeitia R. et al. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells. Thromb Haemost 2010; 103: 525-534.
• 24 Patrizia S, Arcangelo L, Carlo S. Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia. Br J Haematol 2011; 152: 365.
• 25 Lebrin F, Srun S, Raymond K. et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16: 420-428.
• 26 Ades EW, Candal FJ, Swerlick RA. et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 99: 683-690.
• 27 Hoak JC, Warner ED, Cheng HF. et al. Hemangioma with thrombocytopenia and microangiopathic anemia (Kasabach-Merritt syndrome): an animal model. J Lab Clin Med 1971; 77: 941-950.
• 28 Albiñana V, Sanz-Rodriguez F, Recio-Poveda L. et al. Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-beta1 signaling in endothelial cells. Mol Pharmacol 2011; 79: 833-843.
• 29 Sanchez-Elsner T, Botella LM, Velasco B. et al. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002; 277: 43799-43808.
• 30 Garrido-Martin EM, Blanco FJ, Fernandez LA. et al. Characterization of the human Activin-A receptor type II-like kinase 1 (ACVRL1) promoter and its regulation by Sp1. BMC Mol Biol 2010; 11: 51.
• 31 Suzuki Y, Shimada J, Shudo K. et al. Physical interaction between retinoic acid receptor and Sp1: mechanism for induction of urokinase by retinoic acid. Blood 1999; 93: 4264-4276.
• 32 van Zonneveld AJ, Curriden SA, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci USA 1988; 85: 5525-5529.
• 33 Goumans MJ, Valdimarsdottir G, Itoh S. et al. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002; 21: 1743-1753.
• 34 Peracchia F, Polentarutti N, Colotta F. et al. Increased expression of urokinase mRNA in bovine aortic endothelial cells treated with Propranolol. Biochem Biophys Res Commun 1989; 160: 977-981.
• 35 Sabba C, Gallitelli M, Palasciano G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 926.
• 36 Kwaan HC, Silverman S. Fibrinolytic activity in lesions of here ditary hemorrhagic telangiectasia. Arch Dermatol 1973; 107: 571-573.
• 37 Lebrin F, Goumans MJ, Jonker L. et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 2004; 23: 4018-4028.
• 38 Fodstad P, Dheyauldeen S, Rinde M. et al. Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia. Ann Hematol 2011; 90: 611-612.
• 39 Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2010; 278: 16-27.
• 40 Olitsky SE. Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Am J Otolaryngol. 2011 epub ahead of print
• 41 Brommer EJ, Derkx FH, Barrett-Bergshoeff MM. et al. The inability of propranolol and aspirin to inhibit the response of fibrinolytic activity and factor VIII-antigen to infusion of DDAVP. Thromb Haemost 1984; 51: 42-44.
• 42 Schönauer V, Giannini S, Christ G. et al. The effect of beta-receptor blockade on factor VIII levels and thrombin generation in patients with venous thromboembolism. Thromb Haemost 2003; 89: 837-841.